Advances in antiretroviral and anti-hepatitis C virus infection therapy: A report from CROI 2012 - March 5-8, Seattle, Oregon, USA

Research output: Contribution to journalArticle


The Conference on Retroviruses and Opportunistic Infections (CROI) remains a venue for important exchanges of information and dissemination of knowledge. New anti-hepatitis C virus (HCV) therapies remain a focus of interest at CROI 2012. Telaprevir and boceprevir, two recently approved, direct-acting anti-HCV drugs, have now been associated with improved virological responses in patients co-infected with HIV and hepatitis C. However, overlapping toxicities and substantial drug-drug interactions will severely limit their clinical utility. Yet another single-pill, once-daily antiretroviral regimen is on the horizon, and the proof of concept for purging HIV from latent CD4+ cells may have been provided at CROI 2012.

Original languageEnglish (US)
Pages (from-to)369-374
Number of pages6
JournalDrugs of the Future
Issue number5
StatePublished - 2012



  • Boceprevir
  • Dolutegravir
  • Elvitegravir
  • Hepatitis
  • HIV
  • Telaprevir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this